Selected research
Industry Research
Life Science CDMO Industry Research Report 2026
Market perspective
The global Life Science CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Life Science CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Life Science CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Life Science CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Life Science CDMO include Lonza Group, Thermo Fisher Scientific, Catalent, WuXi Biologics, Samsung Biologics, Siegfried, Fujifilm Diosynth Biotechnologies, Lars Petersen and Recipharm, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Life Science CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Life Science CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Life Science CDMO Market by Company
Lonza Group
Thermo Fisher Scientific
Catalent
WuXi Biologics
Samsung Biologics
Siegfried
Fujifilm Diosynth Biotechnologies
Lars Petersen
Recipharm
Boehringer Ingelheim
MilliporeSigma
Aenova Group
AGC Parma Chemicals
GenScript
Novartis
Sai Life Sciences
Life Science CDMO Segment by Type
Active Pharmaceutical Ingredient (API) CDMO
Biologics CDMO
Finished Dosage Form (FDF) CDMO
Others
Life Science CDMO Segment by Application
Pharmaceutical
Clinical
Research
Life Science CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Life Science CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Life Science CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Life Science CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Life Science CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Active Pharmaceutical Ingredient (API) CDMO
- Biologics CDMO
- Finished Dosage Form (FDF) CDMO
- Others
Applications
- Pharmaceutical
- Clinical
- Research
Companies covered
- Lonza Group
- Thermo Fisher Scientific
- Catalent
- WuXi Biologics
- Samsung Biologics
- Siegfried
- Fujifilm Diosynth Biotechnologies
- Lars Petersen
- Recipharm
- Boehringer Ingelheim
- MilliporeSigma
- Aenova Group
- AGC Parma Chemicals
- GenScript
- Novartis
- Sai Life Sciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Life Science CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Active Pharmaceutical Ingredient (API) CDMO
- 2.2.3 Biologics CDMO
- 2.2.4 Finished Dosage Form (FDF) CDMO
- 2.2.5 Others
- 2.3 Life Science CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical
- 2.3.3 Clinical
- 2.3.4 Research
- 2.4 Assumptions and Limitations
3 Life Science CDMO Breakdown Data by Type
- 3.1 Global Life Science CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Life Science CDMO Forecasted Market Size by Type (2027-2032)
4 Life Science CDMO Breakdown Data by Application
- 4.1 Global Life Science CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Life Science CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Life Science CDMO Market Perspective (2021-2032)
- 5.2 Global Life Science CDMO Growth Trends by Region
- 5.2.1 Global Life Science CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Life Science CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Life Science CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Life Science CDMO Market Dynamics
- 5.3.1 Life Science CDMO Industry Trends
- 5.3.2 Life Science CDMO Market Drivers
- 5.3.3 Life Science CDMO Market Challenges
- 5.3.4 Life Science CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Life Science CDMO Players by Revenue
- 6.1.1 Global Top Life Science CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Life Science CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Life Science CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Life Science CDMO Head Office and Area Served
- 6.4 Global Life Science CDMO Players, Product Type & Application
- 6.5 Global Life Science CDMO Manufacturers Established Date
- 6.6 Global Life Science CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Life Science CDMO Market Size (2021-2032)
- 7.2 North America Life Science CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Life Science CDMO Market Size by Country (2021-2026)
- 7.4 North America Life Science CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Life Science CDMO Market Size (2021-2032)
- 8.2 Europe Life Science CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Life Science CDMO Market Size by Country (2021-2026)
- 8.4 Europe Life Science CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Life Science CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Life Science CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Life Science CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Life Science CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Life Science CDMO Market Size (2021-2032)
- 10.2 South America Life Science CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Life Science CDMO Market Size by Country (2021-2026)
- 10.4 South America Life Science CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Life Science CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Life Science CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Life Science CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Life Science CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Lonza Group
- 12.1.1 Lonza Group Company Information
- 12.1.2 Lonza Group Business Overview
- 12.1.3 Lonza Group Revenue in Life Science CDMO Business (2021-2026)
- 12.1.4 Lonza Group Life Science CDMO Product Portfolio
- 12.1.5 Lonza Group Recent Developments
- 12.2 Thermo Fisher Scientific
- 12.2.1 Thermo Fisher Scientific Company Information
- 12.2.2 Thermo Fisher Scientific Business Overview
- 12.2.3 Thermo Fisher Scientific Revenue in Life Science CDMO Business (2021-2026)
- 12.2.4 Thermo Fisher Scientific Life Science CDMO Product Portfolio
- 12.2.5 Thermo Fisher Scientific Recent Developments
- 12.3 Catalent
- 12.3.1 Catalent Company Information
- 12.3.2 Catalent Business Overview
- 12.3.3 Catalent Revenue in Life Science CDMO Business (2021-2026)
- 12.3.4 Catalent Life Science CDMO Product Portfolio
- 12.3.5 Catalent Recent Developments
- 12.4 WuXi Biologics
- 12.4.1 WuXi Biologics Company Information
- 12.4.2 WuXi Biologics Business Overview
- 12.4.3 WuXi Biologics Revenue in Life Science CDMO Business (2021-2026)
- 12.4.4 WuXi Biologics Life Science CDMO Product Portfolio
- 12.4.5 WuXi Biologics Recent Developments
- 12.5 Samsung Biologics
- 12.5.1 Samsung Biologics Company Information
- 12.5.2 Samsung Biologics Business Overview
- 12.5.3 Samsung Biologics Revenue in Life Science CDMO Business (2021-2026)
- 12.5.4 Samsung Biologics Life Science CDMO Product Portfolio
- 12.5.5 Samsung Biologics Recent Developments
- 12.6 Siegfried
- 12.6.1 Siegfried Company Information
- 12.6.2 Siegfried Business Overview
- 12.6.3 Siegfried Revenue in Life Science CDMO Business (2021-2026)
- 12.6.4 Siegfried Life Science CDMO Product Portfolio
- 12.6.5 Siegfried Recent Developments
- 12.7 Fujifilm Diosynth Biotechnologies
- 12.7.1 Fujifilm Diosynth Biotechnologies Company Information
- 12.7.2 Fujifilm Diosynth Biotechnologies Business Overview
- 12.7.3 Fujifilm Diosynth Biotechnologies Revenue in Life Science CDMO Business (2021-2026)
- 12.7.4 Fujifilm Diosynth Biotechnologies Life Science CDMO Product Portfolio
- 12.7.5 Fujifilm Diosynth Biotechnologies Recent Developments
- 12.8 Lars Petersen
- 12.8.1 Lars Petersen Company Information
- 12.8.2 Lars Petersen Business Overview
- 12.8.3 Lars Petersen Revenue in Life Science CDMO Business (2021-2026)
- 12.8.4 Lars Petersen Life Science CDMO Product Portfolio
- 12.8.5 Lars Petersen Recent Developments
- 12.9 Recipharm
- 12.9.1 Recipharm Company Information
- 12.9.2 Recipharm Business Overview
- 12.9.3 Recipharm Revenue in Life Science CDMO Business (2021-2026)
- 12.9.4 Recipharm Life Science CDMO Product Portfolio
- 12.9.5 Recipharm Recent Developments
- 12.10 Boehringer Ingelheim
- 12.10.1 Boehringer Ingelheim Company Information
- 12.10.2 Boehringer Ingelheim Business Overview
- 12.10.3 Boehringer Ingelheim Revenue in Life Science CDMO Business (2021-2026)
- 12.10.4 Boehringer Ingelheim Life Science CDMO Product Portfolio
- 12.10.5 Boehringer Ingelheim Recent Developments
- 12.11 MilliporeSigma
- 12.11.1 MilliporeSigma Company Information
- 12.11.2 MilliporeSigma Business Overview
- 12.11.3 MilliporeSigma Revenue in Life Science CDMO Business (2021-2026)
- 12.11.4 MilliporeSigma Life Science CDMO Product Portfolio
- 12.11.5 MilliporeSigma Recent Developments
- 12.12 Aenova Group
- 12.12.1 Aenova Group Company Information
- 12.12.2 Aenova Group Business Overview
- 12.12.3 Aenova Group Revenue in Life Science CDMO Business (2021-2026)
- 12.12.4 Aenova Group Life Science CDMO Product Portfolio
- 12.12.5 Aenova Group Recent Developments
- 12.13 AGC Parma Chemicals
- 12.13.1 AGC Parma Chemicals Company Information
- 12.13.2 AGC Parma Chemicals Business Overview
- 12.13.3 AGC Parma Chemicals Revenue in Life Science CDMO Business (2021-2026)
- 12.13.4 AGC Parma Chemicals Life Science CDMO Product Portfolio
- 12.13.5 AGC Parma Chemicals Recent Developments
- 12.14 GenScript
- 12.14.1 GenScript Company Information
- 12.14.2 GenScript Business Overview
- 12.14.3 GenScript Revenue in Life Science CDMO Business (2021-2026)
- 12.14.4 GenScript Life Science CDMO Product Portfolio
- 12.14.5 GenScript Recent Developments
- 12.15 Novartis
- 12.15.1 Novartis Company Information
- 12.15.2 Novartis Business Overview
- 12.15.3 Novartis Revenue in Life Science CDMO Business (2021-2026)
- 12.15.4 Novartis Life Science CDMO Product Portfolio
- 12.15.5 Novartis Recent Developments
- 12.16 Sai Life Sciences
- 12.16.1 Sai Life Sciences Company Information
- 12.16.2 Sai Life Sciences Business Overview
- 12.16.3 Sai Life Sciences Revenue in Life Science CDMO Business (2021-2026)
- 12.16.4 Sai Life Sciences Life Science CDMO Product Portfolio
- 12.16.5 Sai Life Sciences Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst